Although CMA seems to act as a compensatory mechanism for lipophagy inhibition in NASH liver, it is reasonable to hypothesize that the persistent biogenesis of small LDs coated by PLIN2, PLIN3, and PLIN5 may not be counteracted. The gene discussed is PLIN2; the disease is metabolic dysfunction-associated steatohepatitis.